Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2011

View Archived Issues

Beta-adrenoceptor antagonist prevents retrieval of cocaine-associated memory in rats

Aeterna Zentaris completes phase III trial of first oral adult growth hormone deficiency diagnostic

Sanlugen prepares novel cytarabine prodrugs

New glucokinase activators patented by Advinus Therapeutics

New glucagon GLP1 receptor agonists presented by Novo Nordisk

Merck KGaA team discloses novel PDK1 inhibitors

Interim phase II data presented on combination regimen including VX-222 in chronic hepatitis C

Granulins gene therapy prevents plaques and synapse loss in mouse model of Alzheimer's disease

Interim data presented from phase II etravirine trial in HIV-1-infected children/adolescents

Update on planned MAA for Nuedexta in pseudobulbar affect

Gamma-secretase inhibitor BMS-708163 evaluated in healthy subjects and in patients with AD

Belgian university designs new agents for HIV infection

BioDelivery Sciences completes phase III BEMA Buprenorphine study

BioWa and arGEN-X enter license agreement for Potelligent technology

Enrollment complete in phase III trial of perifosine/capecitabine in colorectal cancer

Advaxis revises protocol for phase II ADXS-HPV trial

FDA accepts peginesatide NDA for review

Randomized trial evaluates effects of tesamorelin in adults with mild cognitive impairment

Dyax licenses antibody phage display libraries to Kadmon

Trius Therapeutics and Bayer sign torezolid deal

Sunshine Biopharma completes preclinical mechanism of clearance study of lead anticancer product

SkyePharma licenses asthma treatment candidate to Sanofi in Latin America

Tacrolimus approved for new indication in Japan

EMA accepts Eisai's application to extend use of zonisamide

University of British Columbia to study ProtoKinetix's AAGP platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...